Literature DB >> 16906474

Structural and functional changes in peripheral vasculature of Fabry patients.

Riikka J Kalliokoski1, Kari K Kalliokoski, Maila Penttinen, Ilkka Kantola, Aila Leino, Jorma S Viikari, Olli Simell, Pirjo Nuutila, Olli T Raitakari.   

Abstract

OBJECTIVE: Fabry disease is a lysosomal storage disorder due to deficient alpha-galactosidase A activity, which leads to glycosphingolipid accumulation especially in vascular smooth-muscle and endothelial cells. Little is known about the effects of Fabry disease on peripheral artery function and structure. Therefore, we aimed to further characterize the peripheral vascular structural and functional changes in Fabry disease. METHODS AND
RESULTS: We measured structural and functional vascular parameters, including intima-media thickness (IMT) of brachial and carotid arteries and abdominal aorta, carotid and aortic compliance, and brachial artery flow-mediated dilatation (FMD) in 17 Fabry patients and 34 healthy controls matched for age, sex and smoking. Carotid IMT (0.64 +/- 0.15 vs 0.57 +/- 0.12 mm), brachial IMT (1.02 +/- 0.25 vs 0.74 +/- 0.18 mm), and aortic IMT (0.31 +/- 0.09 vs 0.26 +/- 0.04 mm) were significantly increased, and brachial FMD was significantly impaired (6.3 +/- 5.0 vs 9.7 +/- 3.9%) in Fabry patients compared to healthy controls (p < 0.05 in all comparisons after adjustments for age, LDL-cholesterol, and systolic blood pressure). No differences were observed in arterial compliance between the groups.
CONCLUSIONS: These data suggest that Fabry disease affects arterial function and structure by disturbing peripheral endothelial function and promoting intima-media thickening.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16906474     DOI: 10.1007/s10545-006-0340-x

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  48 in total

1.  Enhanced endothelium-dependent vasodilation in Fabry disease.

Authors:  G Altarescu; D F Moore; R Pursley; U Campia; S Goldstein; M Bryant; J A Panza; R Schiffmann
Journal:  Stroke       Date:  2001-07       Impact factor: 7.914

2.  Impaired myocardial perfusion reserve but preserved peripheral endothelial function in patients with Fabry disease.

Authors:  R J Kalliokoski; K K Kalliokoski; J Sundell; E Engblom; M Penttinen; I Kantola; O T Raitakari; J Knuuti; P Nuutila
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

3.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

4.  Selective arterial distribution of cerebral hyperperfusion in Fabry disease.

Authors:  D F Moore; P Herscovitch; R Schiffmann
Journal:  J Neuroimaging       Date:  2001-07       Impact factor: 2.486

5.  Alpha-galactosidase A deficiency accelerates atherosclerosis in mice with apolipoprotein E deficiency.

Authors:  Peter F Bodary; Yuechun Shen; Fernando B Vargas; Xiaoming Bi; Kristen A Ostenso; Shufang Gu; James A Shayman; Daniel T Eitzman
Journal:  Circulation       Date:  2005-01-24       Impact factor: 29.690

6.  Arterial remodelling in Fabry disease.

Authors:  P Boutouyrie; S Laurent; B Laloux; O Lidove; J P Grunfeld; D P Germain
Journal:  Acta Paediatr Suppl       Date:  2002

7.  Atherosclerosis precursors in Finnish children and adolescents. I. General description of the cross-sectional study of 1980, and an account of the children's and families' state of health.

Authors:  H K Akerblom; J Viikari; M Uhari; L Räsänen; T Byckling; K Louhivuori; E Pesonen; P Suoninen; M Pietikäinen; P L Lähde
Journal:  Acta Paediatr Scand Suppl       Date:  1985

Review 8.  An analysis of the relationship between central aortic and peripheral upper limb pressure waves in man.

Authors:  M Karamanoglu; M F O'Rourke; A P Avolio; R P Kelly
Journal:  Eur Heart J       Date:  1993-02       Impact factor: 29.983

9.  Peripheral hemodynamics in patients with Fabry's disease.

Authors:  Y Seino; J K Vyden; M Philippart; H B Rose; K Nagasawa
Journal:  Am Heart J       Date:  1983-05       Impact factor: 4.749

10.  Sequelae of storage in Fabry disease--pathology and comparison with other lysosomal storage diseases.

Authors:  M Elleder
Journal:  Acta Paediatr Suppl       Date:  2003-12
View more
  18 in total

1.  Increased arterial stiffness is associated with high cardiovascular mortality in male Fabry patients.

Authors:  Kathleen Nicholls
Journal:  J Inherit Metab Dis       Date:  2011-12-14       Impact factor: 4.982

Review 2.  [Females with Fabry's disease - an interdisciplinary diagnostic and therapeutic challenge].

Authors:  Frank Weidemann; Markus Niemann; Claudia Sommer; Meinrad Beer; Frank Breunig; Christoph Wanner
Journal:  Med Klin (Munich)       Date:  2010-09-28

3.  Lysosomal delivery of therapeutic enzymes in cell models of Fabry disease.

Authors:  D Marchesan; T M Cox; P B Deegan
Journal:  J Inherit Metab Dis       Date:  2012-03-24       Impact factor: 4.982

4.  Endothelial function in children and adolescents with mucopolysaccharidosis.

Authors:  Aaron S Kelly; Andrea M Metzig; Julia Steinberger; Elizabeth A Braunlin
Journal:  J Inherit Metab Dis       Date:  2012-01-10       Impact factor: 4.982

5.  Early cardiovascular remodelling in Fabry disease.

Authors:  Luca Costanzo; Sergio Buccheri; Piera Capranzano; Luigi Di Pino; Giuseppina Curatolo; Margherita Rodolico; Stefano Leggio; Anita Blundo; Corrado Tamburino; Ines Monte
Journal:  J Inherit Metab Dis       Date:  2013-04-25       Impact factor: 4.982

6.  Elevated globotriaosylsphingosine is a hallmark of Fabry disease.

Authors:  Johannes M Aerts; Johanna E Groener; Sijmen Kuiper; Wilma E Donker-Koopman; Anneke Strijland; Roelof Ottenhoff; Cindy van Roomen; Mina Mirzaian; Frits A Wijburg; Gabor E Linthorst; Anouk C Vedder; Saskia M Rombach; Josanne Cox-Brinkman; Pentti Somerharju; Rolf G Boot; Carla E Hollak; Roscoe O Brady; Ben J Poorthuis
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-19       Impact factor: 11.205

7.  Genetic polymorphisms of vitamin D receptor (VDR) in Fabry disease.

Authors:  Michael Teitcher; Sarah Weinerman; Catharina Whybra; Michael Beck; Nir Sharon; Deborah Elstein; Gheona Altarescu
Journal:  Genetica       Date:  2008-02-16       Impact factor: 1.082

Review 8.  Unusual renal presentation of Fabry disease in a female patient.

Authors:  Cataldo Abaterusso; Vincenzo De Biase; Alessandro Salviati; Antonia Fabris; Deborah Millardi; Paola Tomei; Patrizia Bernich; Antonio Lupo; Giovanni Gambaro
Journal:  Nat Rev Nephrol       Date:  2009-04-28       Impact factor: 28.314

9.  Enzyme replacement therapy stabilizes obstructive pulmonary Fabry disease associated with respiratory globotriaosylceramide storage.

Authors:  R Y Wang; J T Abe; A H Cohen; W R Wilcox
Journal:  J Inherit Metab Dis       Date:  2008-10-21       Impact factor: 4.982

Review 10.  Anderson-Fabry Disease: From Endothelial Dysfunction to Emerging Therapies.

Authors:  Cosimo A Stamerra; Rita Del Pinto; Paolo di Giosia; Claudio Ferri; Amirhossein Sahebkar
Journal:  Adv Pharmacol Pharm Sci       Date:  2021-05-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.